Morgan Stanley Downgrades Halozyme Therapeutics to Equal-Weight, Lowers Price Target to $62

Benzinga · 05/14/2025 14:12
Morgan Stanley analyst Vikram Purohit downgrades Halozyme Therapeutics (NASDAQ:HALO) from Overweight to Equal-Weight and lowers the price target from $73 to $62.